About this item:

336 Views | 0 Downloads

Author Notes:

Corresponding author: Joe L Hsu: Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University Hospital, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5236, USA. Email: joehsu@stanford.edu.

JLH had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. JLH, AJP and JAR were responsible for study concept and design. JLH, AJP, GSM and JAR were responsible for acquisition of data. JHL and VL were responsible for statistical analysis. JLH, VL, AJP, GSM and JAR were responsible for administrative, technical, and material support. JLH and JAR were responsible for study supervision.

All authors were responsible for analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content.

The authors thank the members of the CIOS for taking the time to complete the practice pattern survey. They would also like to acknowledge Dr Gomathi Krishnan and the Stanford University Center for Clinical Informatics for their assistance with the creation and distribution of the survey.

JAR reports holding stock in Sirius Genomics Inc., which has submitted patents owned by the University of British Columbia (UBC) and licensed to Sirius Genomics, that is related to the genetics of sepsis and its treatment. The UBC has also submitted a patent related to the use of vasopressin in septic shock. JAR reports being an inventor on these patents. JAR reports receiving consulting fees from Ferring Pharmaceuticals (which manufactures vasopressin and is developing a selective V1a agonist), from Astra Zeneca (which is developing an anti-TNFα), from BioCritica (which used to sell activated protein C in the USA), from MeImmune, and from Sirius Genomics Inc. JAR reports having received grant support from Sirius Genomics, Ferring Pharmaceuticals, Astra Zeneca and Eli Lilly that is provided to and administered by the UBC. JAR has received speaking honoraria from Pfizer and Eli Lilly.

Subjects:

Potential for overuse of corticosteroids and vasopressin in septic shock

Tools:

Journal Title:

Critical Care

Volume:

Volume 16, Number 5

Publisher:

, Pages 447-447

Type of Work:

Article | Post-print: After Peer Review

Copyright information:

© 2012 BioMed Central Ltd

Export to EndNote